Emcure expands injectables capacity, opens 3rd facility in Gujarat
时间:2024-06-26 05:41:20 阅读(143)
The third injectable facility of Emcure Pharmaceuticals in Mehsana, Gujarat, which was commissioned in August 2023, is now ready for commercial supplies to domestic and international markets. The company already has an oral formulations manufacturing line in Mehsana.
It also has a facility in Hinjawadi, Pune, with a capacity of 80.64 million vials per annum and another in Sanand, Gujarat, with a capacity to churn out 72 million vials per annum.
IPO-bound Emcure’s manufacturing operations cover oral solids, oral liquids and injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs. The company’s subsidiary Gennova Biopharmaceuticals,also plans to use its mRNA platform, through which it launched the Covid-19 vaccine, forthree other vaccines for Zoster, Zika and Rabies.
Emcure’s injectable portfolio includes complex iron injectables, oncology, steroids, suspensions and emulsions. Emcure can produce high-potency injectables, particularly oncology products.
Emcure had filed a draft red herring prospectus (DRHP) on December 16 for its Rs 800 crore IPO. It is the 12th largest Indian pharmaceutical company and the largest pharmaceutical company in the gynaecology, blood-related and HIV antiviral therapeutics segment in the country.
For the international markets, the firm’s focus is on developing and commercialising products, which requires significant expertise and is subject to less competition and offers higher margins.
In Europe and other key target markets, they are focused on higher-value-added generics and complex injectables, such as Cidofovir and Meropenem. Europe is one of the focus areas in the hospital segment, as it is a large market for complex injectables products, such as Cidofovir, BiCNU and Treprostinil, the company’s DRHP said.
The company is working on `ready-to-use’ products that reduce multi-step dose preparation and enable ease of use by physicians.
上一篇:NSE FO ban- Ambuja Cements under ban on Wednesday, February 1, 2023
下一篇:Yes Bank shares rally 20% over two sessions; here’s why the stock is surging in trade
猜你喜欢
- Kaynes Technology IPO set to open on November 10
- NSE F&O Ban- India Cements, GNFC, SAIL, Delta Corp, other stocks under ban on August 17, Thursday
- Maruti Suzuki, SBI Life Insurance, Mahindra Lifespace, Dalmia Bharat stocks on ‘Buy’ list of HDFC Securities
- Nuvama , Cushman & Wakefield to float Rs 3000 crore office fund
- Jindal Stainless, IDFC, Adani Total Gas among 42 NSE stocks to hit 52-week high, 61 falls to 52-week low
- Markets to take cues from macro data, global trends- Analysts
- Larsen & Toubro sets ball rolling on Rs 10,000 cr buyback
- Mcap of seven of top-10 most valued firms erode by Rs 1 lakh cr; State Bank of India biggest laggard
- Karni Sena chief murder- NIA raids 31 locations in Haryana, Rajasthan against suspects linked to killing